All In Biotech

NDA 217294 · Sq Innovation

Lasix Onyu

Furosemide · Subcutaneous · Loop Diuretic

Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Oct 7, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

345

66 Phase 3, 33 recruiting

FAERS reports

265,538

219,231 serious, 40,876 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 14, 2025.

Lasix ONYU is a loop diuretic indicated for the treatment of edema in adult patients with chronic heart failure. ( 1.1 ) 1.1 Congestion Lasix ONYU is indicated for the treatment of edema in adult patients with chronic heart failure. 1.1 Congestion Lasix ONYU is indicated for the treatment of edema in adult patients with chronic heart failure.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 7, 2025 Original approval · Type 3 - New Dosage Form LabelLetter
1 products under this application
  • LASIX ONYU · FUROSEMIDE 80MG/2.67ML (30MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Furosemide" as an intervention, any sponsor and status, largest first.

All 345 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea18,437
  • acute kidney injury16,467
  • fatigue13,248
  • diarrhoea13,195
  • death12,368
  • nausea11,534
  • fall11,003
  • off label use10,842
  • drug ineffective10,424
  • hypotension10,330
  • pneumonia10,172
  • dizziness9,887

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,479
20053,857
20063,623
20073,214
20083,608
20093,997
20104,832
20116,479
20127,274
20137,405
201410,059
201513,254
201616,201
201716,716
201821,192
201923,004
202020,355
202118,734
202216,306
202316,473
202417,411
202516,227
202611,831

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,427 on PubMed

Sponsor: Sq Innovation

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.